NkGen Biotech will present Troculeucel, a cryopreserved autologous NK cell therapy, at BIOCHINA 2026, with Phase 2 trials underway for Alzheimer's disease and potential expansion into ALS, frontotemporal dementia, and Parkinson's disease. The therapy represents a cell-based approach to neurodegenerative conditions where conventional pharmacology has shown limited efficacy.
Key Points
- Troculeucel uses enhanced autologous NK cells in cryopreserved form
- Phase 2 trial active for Alzheimer's; expansion planned for multiple neurodegenerative conditions
- Company exploring regulatory pathways and manufacturing partnerships in China
Longevity Analysis
Cell-based immunotherapies targeting neurodegenerative disease represent a fundamental shift from symptom management toward restoring the body's capacity to defend and regenerate compromised neural tissue. NK cells modulate immune surveillance and eliminate dysfunctional cells—processes that deteriorate with age and contribute to neuroinflammation and protein accumulation in Alzheimer's and related disorders. Success in this Phase 2 program would establish autologous cell therapy as a viable intervention for conditions where the nervous system's own regenerative and defensive capacity has become insufficient, expanding the therapeutic toolkit beyond current symptomatic approaches.
Original published by Longevity.Technology.